RU2761824C2 - Ингибиторы CDK8/19 - Google Patents

Ингибиторы CDK8/19 Download PDF

Info

Publication number
RU2761824C2
RU2761824C2 RU2018128415A RU2018128415A RU2761824C2 RU 2761824 C2 RU2761824 C2 RU 2761824C2 RU 2018128415 A RU2018128415 A RU 2018128415A RU 2018128415 A RU2018128415 A RU 2018128415A RU 2761824 C2 RU2761824 C2 RU 2761824C2
Authority
RU
Russia
Prior art keywords
substituted
unsubstituted
alkyl
cancer
pyrazol
Prior art date
Application number
RU2018128415A
Other languages
English (en)
Russian (ru)
Other versions
RU2018128415A (ru
RU2018128415A3 (https=
Inventor
Алексей Леонидович Миндич
Анна Юрьевна Честнова
Мария Андреевна Касаткина
Андрей Иванович Алафинов
Алексей Сергеевич Гаврилов
Антон Александрович Евдокимов
Лилиана Вячеславовна Леншмидт
Елена Александровна Максименко
Мария Сергеевна Мишина
Сергей Александрович Силонов
Евгений Юрьевич Смирнов
Павел Андреевич Яковлев
Дмитрий Валентинович Морозов
Original Assignee
Закрытое Акционерное Общество "Биокад"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2018128415A priority Critical patent/RU2761824C2/ru
Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"
Priority to PE2021000162A priority patent/PE20210416A1/es
Priority to BR112021001939-1A priority patent/BR112021001939A2/pt
Priority to PCT/RU2019/050123 priority patent/WO2020027704A1/ru
Priority to KR1020217006527A priority patent/KR102926889B1/ko
Priority to MX2021001335A priority patent/MX2021001335A/es
Priority to CA3108298A priority patent/CA3108298A1/en
Priority to EA202190452A priority patent/EA202190452A1/ru
Priority to US17/264,670 priority patent/US11840531B2/en
Priority to JP2021505964A priority patent/JP7365396B2/ja
Priority to MA52375A priority patent/MA52375B2/fr
Priority to CN201980065665.1A priority patent/CN113166140B/zh
Priority to EP19844331.9A priority patent/EP3831829A4/en
Priority to AU2019313199A priority patent/AU2019313199B2/en
Priority to TW108127569A priority patent/TWI839374B/zh
Priority to ARP190102200A priority patent/AR115898A1/es
Publication of RU2018128415A publication Critical patent/RU2018128415A/ru
Priority to CONC2021/0001174A priority patent/CO2021001174A2/es
Priority to CL2021000282A priority patent/CL2021000282A1/es
Priority to PH12021550258A priority patent/PH12021550258A1/en
Publication of RU2018128415A3 publication Critical patent/RU2018128415A3/ru
Application granted granted Critical
Publication of RU2761824C2 publication Critical patent/RU2761824C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018128415A 2018-08-03 2018-08-03 Ингибиторы CDK8/19 RU2761824C2 (ru)

Priority Applications (19)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19
CN201980065665.1A CN113166140B (zh) 2018-08-03 2019-07-31 Cdk8/19抑制剂
PCT/RU2019/050123 WO2020027704A1 (ru) 2018-08-03 2019-07-31 Ингибиторы cdk8/19
KR1020217006527A KR102926889B1 (ko) 2018-08-03 2019-07-31 Cdk8/19 저해제
MX2021001335A MX2021001335A (es) 2018-08-03 2019-07-31 Inhibidores de ckd8/19.
CA3108298A CA3108298A1 (en) 2018-08-03 2019-07-31 Cdk8/19 inhibitors
EA202190452A EA202190452A1 (ru) 2018-08-03 2019-07-31 Ингибиторы cdk8/19
US17/264,670 US11840531B2 (en) 2018-08-03 2019-07-31 CDK8/19 inhibitors
JP2021505964A JP7365396B2 (ja) 2018-08-03 2019-07-31 Ｃｄｋ８／１９阻害薬
AU2019313199A AU2019313199B2 (en) 2018-08-03 2019-07-31 CDK8/19 inhibitors
PE2021000162A PE20210416A1 (es) 2018-08-03 2019-07-31 Inhibidores de ckd8/19
BR112021001939-1A BR112021001939A2 (pt) 2018-08-03 2019-07-31 inibidores de cdk8/19
MA52375A MA52375B2 (fr) 2018-08-03 2019-07-31 Inhibiteurs de cdk8/19
EP19844331.9A EP3831829A4 (en) 2018-08-03 2019-07-31 CDK8/19 INHIBITORS
TW108127569A TWI839374B (zh) 2018-08-03 2019-08-02 Cdk8/19抑制劑
ARP190102200A AR115898A1 (es) 2018-08-03 2019-08-02 1,7-naftiridinas como inhibidores de cdk8/19
CONC2021/0001174A CO2021001174A2 (es) 2018-08-03 2021-02-02 Inhibidores de ckd8/19
CL2021000282A CL2021000282A1 (es) 2018-08-03 2021-02-02 Inhibidores de ckd8/19
PH12021550258A PH12021550258A1 (en) 2018-08-03 2021-02-03 Cdk8/19 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19

Publications (3)

Publication Number Publication Date
RU2018128415A RU2018128415A (ru) 2020-02-04
RU2018128415A3 RU2018128415A3 (https=) 2021-03-30
RU2761824C2 true RU2761824C2 (ru) 2021-12-13

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19

Country Status (19)

Country Link
US (1) US11840531B2 (https=)
EP (1) EP3831829A4 (https=)
JP (1) JP7365396B2 (https=)
KR (1) KR102926889B1 (https=)
CN (1) CN113166140B (https=)
AR (1) AR115898A1 (https=)
AU (1) AU2019313199B2 (https=)
BR (1) BR112021001939A2 (https=)
CA (1) CA3108298A1 (https=)
CL (1) CL2021000282A1 (https=)
CO (1) CO2021001174A2 (https=)
EA (1) EA202190452A1 (https=)
MA (1) MA52375B2 (https=)
MX (1) MX2021001335A (https=)
PE (1) PE20210416A1 (https=)
PH (1) PH12021550258A1 (https=)
RU (1) RU2761824C2 (https=)
TW (1) TWI839374B (https=)
WO (1) WO2020027704A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2535671C1 (ru) * 2010-10-18 2014-12-20 Раквалиа Фарма Инк. Производные ариламидов в качестве блокаторов ttx-s
WO2015014768A1 (en) * 2013-07-29 2015-02-05 F. Hoffmann-La Roche Ag 1,7-naphthyridine derivatives
US20160016951A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
WO2017202719A1 (en) * 2016-05-23 2017-11-30 Boehringer Ingelheim International Gmbh New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
MX2010006244A (es) * 2007-12-06 2010-12-02 Schering Corp Moduladores de gamma secretasa.
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2535671C1 (ru) * 2010-10-18 2014-12-20 Раквалиа Фарма Инк. Производные ариламидов в качестве блокаторов ttx-s
WO2015014768A1 (en) * 2013-07-29 2015-02-05 F. Hoffmann-La Roche Ag 1,7-naphthyridine derivatives
US20160016951A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
WO2017202719A1 (en) * 2016-05-23 2017-11-30 Boehringer Ingelheim International Gmbh New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors

Also Published As

Publication number Publication date
TW202012406A (zh) 2020-04-01
AU2019313199A1 (en) 2021-03-11
RU2018128415A (ru) 2020-02-04
PE20210416A1 (es) 2021-03-04
CO2021001174A2 (es) 2021-02-26
BR112021001939A2 (pt) 2021-04-27
MX2021001335A (es) 2021-04-12
CN113166140B (zh) 2024-06-14
CN113166140A (zh) 2021-07-23
EP3831829A1 (en) 2021-06-09
CL2021000282A1 (es) 2021-08-13
JP7365396B2 (ja) 2023-10-19
AR115898A1 (es) 2021-03-10
AU2019313199B2 (en) 2023-07-06
RU2018128415A3 (https=) 2021-03-30
EA202190452A1 (ru) 2021-04-13
US11840531B2 (en) 2023-12-12
MA52375B2 (fr) 2023-02-28
PH12021550258A1 (en) 2021-10-11
WO2020027704A1 (ru) 2020-02-06
TWI839374B (zh) 2024-04-21
MA52375A1 (fr) 2021-12-31
US20210246138A1 (en) 2021-08-12
KR102926889B1 (ko) 2026-02-19
EP3831829A4 (en) 2022-04-20
CA3108298A1 (en) 2020-02-06
KR20210040416A (ko) 2021-04-13
JP2021533143A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
EP3129380B1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
CN117683049A (zh) 作为ras抑制剂以治疗癌症的吲哚衍生物
JP7365332B2 (ja) Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
CN115443276A (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
CN115397818A (zh) 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
RU2761824C2 (ru) Ингибиторы CDK8/19
RU2763347C2 (ru) Новые ингибиторы cdk8/19
RU2754441C2 (ru) Новые ингибиторы cdk8/19
RU2739489C2 (ru) Новые гетероциклические соединения как ингибиторы CDK8/19
EA042225B1 (ru) Ингибиторы cdk8/19
RU2851298C2 (ru) Новые ингибиторы JAK1-киназ
RU2852021C2 (ru) Новые ингибиторы JAK1-киназ
HK40058347A (en) Cdk8/19 inhibitors
HK40058347B (zh) Cdk8/19抑制剂
KR20250078953A (ko) 사이클린-의존성 키나아제 7 억제제
CA3268634A1 (en) Cyclin-dependent kinase 7 inhibitors
TW202120511A (zh) 雜環化合物
BR112020002674B1 (pt) Compostos heterocíclicos como inibidoresde cdk8/19, método para inibir a atividade biológica de quinases de proteína, composição farmacêutica, método para tratamento de uma doença ou distúrbio e uso do composto ou sal farmaceuticamente aceitável do mesmo
EA041908B1 (ru) Производные 1,7-нафтиридина и их применение в качестве ингибиторов cdk8/19
HK1252365B (en) Spiro[3h-indole-3,2’-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
HK1252365A1 (en) Spiro[3h-indole-3,2’-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors